By way of example, omalizumab, an IgE-specific humanized monoclonal antibody, reduces serum IgE levels and asthma exacerbations, but has only mildly beneficial effects on forced expiratory volume in 1 s (FEV1). This evidence concerns the gene IGHE and asthma.